These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 11025988)

  • 1. [Estrogen and progesterone receptors in breast cancer].
    Sonoo H
    Nihon Rinsho; 2000 Apr; 58 Suppl():146-53. PubMed ID: 11025988
    [No Abstract]   [Full Text] [Related]  

  • 2. [Long-term results of adjuvant endocrine therapy for hormone receptor-positive breast cancer].
    Semilgazov VF; Manikhas AG; Semiglazov VV; Bozhok AA; Dashian GA; Ivanov VG; Paltuev RM; Vasil'ev AG; Shchedrin DE; Ermachenkova AM; Nikitina IV; Pen'kov KD; Bessonov AA; Tabagua TT; Kolar'kova VV
    Vopr Onkol; 2011; 57(5):567-77. PubMed ID: 22238925
    [No Abstract]   [Full Text] [Related]  

  • 3. [Breast neoplasms: predictive factors for endocrine therapy ].
    Hayashi S
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():148-53. PubMed ID: 17682151
    [No Abstract]   [Full Text] [Related]  

  • 4. Can quantifying hormone receptor levels guide the choice of adjuvant endocrine therapy for breast cancer?
    Mackey JR
    J Clin Oncol; 2011 Apr; 29(12):1504-6. PubMed ID: 21422423
    [No Abstract]   [Full Text] [Related]  

  • 5. Progesterone receptor testing: not the right time to be buried.
    Colozza M; Larsimont D; Piccart MJ
    J Clin Oncol; 2005 Jun; 23(16):3867-8; author reply 3869-70. PubMed ID: 15923594
    [No Abstract]   [Full Text] [Related]  

  • 6. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Basic Consensus on endocrinotherapy for breast cancer].
    Jiang ZF; Xu BH; Song ST
    Zhonghua Zhong Liu Za Zhi; 2006 Mar; 28(3):238-9. PubMed ID: 16875616
    [No Abstract]   [Full Text] [Related]  

  • 8. Tamoxifen: an enduring star.
    Veronesi U; Maisonneuve P; Decensi A
    J Natl Cancer Inst; 2007 Feb; 99(4):258-60. PubMed ID: 17312297
    [No Abstract]   [Full Text] [Related]  

  • 9. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study.
    Elledge RM; Green S; Pugh R; Allred DC; Clark GM; Hill J; Ravdin P; Martino S; Osborne CK
    Int J Cancer; 2000 Mar; 89(2):111-7. PubMed ID: 10754487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmaceutical therapy of breast cancer].
    Láng I; Kahán Z; Pintér T; Dank M; Boér K; Pajkos G; Faluhelyi Z; Pikó B; Eckhardt S; Horváth Z
    Magy Onkol; 2010 Sep; 54(3):237-54. PubMed ID: 20870601
    [No Abstract]   [Full Text] [Related]  

  • 11. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
    J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients.
    Chang J; Powles TJ; Allred DC; Ashley SE; Makris A; Gregory RK; Osborne CK; Dowsett M
    Clin Cancer Res; 2000 Feb; 6(2):616-21. PubMed ID: 10690547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The importance of steroid receptors for the prognosis and hormone treatment of breast cancer patients: a retrospective study in Southeastern Netherlands].
    Voogd AC; Crommelin MA; Repelaer van Driel OJ; Tutein Nolthenius-Puylaert MC; Vreugdenhil G; Coebergh JW
    Ned Tijdschr Geneeskd; 1998 Aug; 142(31):1772-8. PubMed ID: 9856143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tamoxifen for early breast cancer.
    Nurs Times; 2001 Jun 21-27; 97(25):41. PubMed ID: 11957988
    [No Abstract]   [Full Text] [Related]  

  • 15. [ASCO/CAP guidelines and recommendations on hormonal receptor testing in breast cancer].
    Wang T; Jiang ZF
    Zhonghua Bing Li Xue Za Zhi; 2010 Nov; 39(11):721-2. PubMed ID: 21215158
    [No Abstract]   [Full Text] [Related]  

  • 16. Aromatase inhibitors for the treatment of breast cancer: is tamoxifen of historical interest only?
    Van Poznak CH; Hayes DF
    J Natl Cancer Inst; 2006 Sep; 98(18):1261-3. PubMed ID: 16985239
    [No Abstract]   [Full Text] [Related]  

  • 17. Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays.
    Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
    J Clin Pathol; 2007 Apr; 60(4):397-404. PubMed ID: 16775123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Déjà vu for breast cancer two?
    Stearns V; Davidson NE
    J Natl Cancer Inst; 2004 Apr; 96(7):497-9. PubMed ID: 15069104
    [No Abstract]   [Full Text] [Related]  

  • 19. Current status of endocrine therapy for advanced breast cancer.
    Bland KI
    Ann Surg Oncol; 1999 Dec; 6(8 Suppl):4S-7S. PubMed ID: 10619452
    [No Abstract]   [Full Text] [Related]  

  • 20. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen.
    Arpino G; Weiss HL; Clark GM; Hilsenbeck SG; Osborne CK
    J Clin Oncol; 2005 Jul; 23(21):4687-94. PubMed ID: 15837971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.